Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

PEG-MGF Dosage Chart - Peptide Dosages

PEG-MGF (2 mg) Dosage Protocol A pegylated, longer-acting mechano growth factor peptide studied for muscle satellite-cell activation and recovery — preclinical only, not FDA-approved. Pegylated synthetic peptide of the MGF (IGF-1Ec) splice variant; reported to

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

PEG-MGF (2 mg) Dosage Protocol

A pegylated, longer-acting mechano growth factor peptide studied for muscle satellite-cell activation and recovery — preclinical only, not FDA-approved.

Pegylated synthetic peptide of the MGF (IGF-1Ec) splice variant; reported to expand the muscle satellite-cell pool, with PEG extending its short half-life.

Micrograms: research conventions cite 200-400 mcg SC, 2-3x weekly, in short 4-6 week cycles — the pegylated form allows less-frequent dosing than native MGF.

Preclinical only — cell and animal data, no human trials, not FDA-approved; no endogenous MGF peptide has ever been isolated in vivo.

Quickstart Highlights

PEG-MGF is a pegylated synthetic peptide based on mechano growth factor (MGF) — the 24-amino-acid C-terminal sequence of an alternatively-spliced variant of the IGF-1 gene (IGF-1Ec) that is transiently up-regulated in skeletal muscle after mechanical loading or injury[2]. In the research-peptide community it is studied for muscle satellite-cell activation and recovery, and is treated as the longer-acting version of MGF: attaching a polyethylene-glycol (PEG) chain slows clearance so it can be dosed a few times a week rather than only immediately post-workout.

An important honesty note underpins everything here: while the IGF-1 splice variant (the mRNA named MGF) is real, no analogous MGF peptide has ever been isolated from cells, tissues or biological fluids — synthetic MGF is a laboratory construct whose actions differ from any known product of the IGF-1 gene[1]. The evidence is preclinical, there are no human trials of PEG-MGF, and it is not FDA-approved. The figures below are research conventions provided strictly for research and educational reference — not medical advice.

Mix & measure PEG-MGF · 2 mg

Pre-filled with this protocol’s recommended BAC water and documented starting dose — edit any field to run your own numbers.

Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Full reconstitution guide → · Advanced calculator →

Supplies Needed

Everything a documented injectable protocol relies on. Nothing here is exotic — sterile technique and accurate microgram measurement matter far more than any single tool.

Protocol Overview

At 1,000 mcg/mL a single 2 mg vial holds 2 mL of usable solution — ten 200 mcg doses, or five 400 mcg doses. At a typical 200–400 mcg, 2–3×-weekly schedule, one vial covers roughly two to five weeks of research use depending on the dose chosen.

PEG-MGF is generally run in short cycles rather than continuously; a common pattern is 4–6 weeks on followed by a break, so one or two vials cover a cycle.

Dosing Protocol

A reference range converted to U-100 units at 1,000 mcg/mL. This is a common research convention, not a titration schedule and not clinical guidance.

Conservative

200 mcg, 2×/week

20 units (0.20 mL)

Common research range

300 mcg, 2–3×/week

30 units (0.30 mL)

Upper reference

400 mcg, 2–3×/week

40 units (0.40 mL)

Cycle length

4–6 weeks, then break

Not run continuously

Why PEG-MGF draws research interest

These are the directions researchers and the peptide community most often explore PEG-MGF for — so you know you’re in the right place. They describe what is being studied, not proven benefits, approved uses, or promised results.

Satellite-cell activation

Synthetic MGF is reported to stimulate proliferation while delaying differentiation of muscle satellite cells in culture, expanding the repair pool.

Recovery interest

The MGF splice variant is the first IGF-1 isoform up-regulated after muscle damage; PEG-MGF is studied as a longer-acting version of that signal.

Longer action than MGF

Pegylation slows clearance so it can be dosed a few times a week rather than only immediately post-workout like native MGF.

Evidence ranges from early laboratory work to clinical trials depending on the use — the sections below cover the actual data and sources.

Add 2.0 mL bacteriostatic water to one 2 mg vial → 1,000 mcg/mL (10 mcg per U-100 unit).

Reference research convention 200–400 mcg, 2–3× per week; conservative work often starts near 200 mcg.

Subcutaneous; the pegylated form is dosed a few times weekly (often on non-training or post-workout days) rather than only immediately after training.

Preclinical / research-chemical — cell and animal data only, no human trials, not FDA-approved.

Dosing & Reconstitution Guide

The whole point of the pegylated form is duration. Native MGF has a very short half-life (a matter of minutes), so it was historically injected immediately after training; adding a PEG chain slows clearance so PEG-MGF can be dosed a few times a week and still maintain exposure[1].

Standard / Gradual Approach

The reference approach is a fixed weekly frequency rather than a slow titration: research protocols commonly cite 200 to 400 mcg per dose, two to three times per week, run for 4 to 6 weeks before a break. Reconstituted at 1,000 mcg/mL, a 200 mcg dose equals 20 units (0.20 mL) on a U-100 syringe and a 400 mcg dose equals 40 units (0.40 mL). Because PEG-MGF is long-acting, dosing it every day is not the convention — the extended half-life is what allows the less-frequent schedule.

Reconstitution Steps

Reconstitution is standard for a lyophilized peptide. A 2 mL diluent volume keeps a 2 mg vial easy to measure and physically sensible.

▪Sanitize: Swab the vial stopper and the bacteriostatic-water vial with fresh alcohol pads and let them dry.

▪Add diluent slowly: Draw 2.0 mL bacteriostatic water and let it run down the inside wall of the vial — do not spray it directly onto the powder.

▪Dissolve gently: Swirl; do not shake. The solution should clear within a minute or two.

▪Store: Label with the date and refrigerate at 2–8 °C; the reconstituted vial holds ~1,000 mcg/mL.

Storage Instructions

Store the lyophilized vial in the freezer or refrigerator away from light until reconstitution.

After reconstitution, keep the vial refrigerated at 2–8 °C and use within the bacteriostatic-water window (commonly cited as up to ~28 days). Discard if the solution becomes cloudy or discolored.

Important Notes

Practical points that keep a microgram-dosed injectable protocol consistent and honest about what the compound is.

▪Pegylation extends half-life: The PEG chain is what lets PEG-MGF be dosed a few times a week rather than only post-workout; without it, native MGF is cleared within minutes[1].

▪The premise is not fully settled: No endogenous MGF peptide has been isolated in vivo, and synthetic MGF’s effects differ from known IGF-1 products — so claims about its physiological role should be read with genuine caution[1].

▪Preclinical only: The proliferation and satellite-cell effects come from cell and animal studies; there are no human trials of PEG-MGF for muscle growth or recovery[3].

▪Sterile technique: Fresh U-100 syringe each injection, straight into a puncture-proof sharps container afterward.

▪Unverified purity: Grey-market PEG-MGF is a synthetic construct whose identity, pegylation and potency vary by source; without a Certificate of Analysis, none of it can be assumed.

How This Works

When skeletal muscle is loaded or damaged, the IGF-1 gene is alternatively spliced and the MGF (IGF-1Ec) mRNA is transiently up-regulated first, correlating with markers of satellite-cell activation, before a later switch toward systemic IGF-1Ea associated with differentiation and repair[2]. The synthetic MGF peptide corresponds to the unique C-terminal portion of that splice variant, and in culture it is reported to promote proliferation of muscle precursor (satellite) cells while delaying their differentiation — expanding the pool of cells available for repair[3].

PEG-MGF is that peptide with a polyethylene-glycol chain attached to slow enzymatic breakdown and renal clearance, extending its window of action. Critically, the reviews that established the MGF splice-variant biology also emphasize that a corresponding MGF peptide has never been isolated from living tissue, and that the synthetic peptide’s activity does not map cleanly onto any confirmed endogenous IGF-1 product[1] — so the mechanism, while biologically motivated, remains outside validated human evidence.

Lifestyle Factors

The reported role of MGF is tied to the muscle’s own response to mechanical loading, so the training stimulus is not incidental — whatever satellite-cell activity the peptide could support still depends on genuine resistance training, adequate protein and recovery to have any substrate to act on.

As a preclinical, non-approved compound it is studied against a backdrop of ordinary health maintenance rather than as a standalone intervention; nothing about it substitutes for sound programming, nutrition and sleep.

Potential Benefits & Side Effects

What the preclinical literature reports; this is cell and animal evidence, not a supervised human therapy, and individual outcomes are unknown because controlled human studies of PEG-MGF do not exist.

Reported Effects

▪Satellite-cell proliferation: Synthetic MGF is reported to stimulate proliferation while delaying differentiation of muscle satellite cells in culture, expanding the precursor pool available for repair[3].

▪Early response to muscle damage: The MGF splice variant is the first IGF-1 isoform up-regulated after mechanical damage, correlating with satellite-cell activation markers — the biological rationale for the recovery interest[2].

▪Mechano-responsive expression: IGF-1 gene splicing toward MGF is driven by mechanical strain in muscle-cell models, linking loading to the proposed repair signal[4].

▪Studied for recovery and longer action: The community interest is faster recovery and muscle growth from a longer-acting MGF — a plausible extrapolation from the pharmacology that has not been confirmed in humans.

Common Side Effects

▪Injection-site reactions: Local redness, soreness or swelling are the most predictable effects of any subcutaneous injection.

▪Growth-signaling caution: As an IGF-1-derived, pro-proliferative peptide, it carries the same theoretical concern about promoting growth of pre-existing abnormal tissue — a genuine reason for caution, especially with any personal or family cancer history.

▪Unknown long-term safety: There is no human safety database for PEG-MGF; effects of repeated cycles and of the PEG carrier itself are not characterized for this use.

▪Purity and identity risk: Because it is a synthetic construct with variable pegylation, contamination or mislabeling is the practical safety concern rather than a well-characterized toxicity.

Injection Technique

Subcutaneous injection technique is standard. Accurate microgram measurement and site rotation matter more than speed.

Pre-Injection Preparation

▪Wash hands; let the refrigerated vial come toward room temperature to reduce sting.

▪Swab the stopper and injection site; let the alcohol dry fully.

▪Draw your microgram dose into a fresh U-100 syringe and tap out air bubbles.

Injection Procedure

▪Pinch a skinfold (abdomen or thigh) and insert at 45–90°.

▪Inject the solution at a steady, even pace.

▪Withdraw and apply light pressure with a clean swab — do not rub.

Post-Injection Care

▪Drop the used syringe straight into a puncture-proof sharps container.

▪Rotate sites across injections to avoid local irritation.

▪Return the vial to the refrigerator promptly.

Recommended Source

For high-purity research peptides, we point researchers to Prime Lab Peptides for PEG-MGF (2 mg Vial).

Why Prime Lab Peptides?

▪Top-rated on Trustpilot: Independently reviewed as the highest-rated peptide lab on Trustpilot — making it the best current source in the USA.

▪Third-party tested: Every batch ships with a Certificate of Analysis (COA) confirming purity and composition.

▪Consistent quality: ISO-aligned manufacturing and handling keep product integrity reliable batch to batch.

▪Cold-chain integrity: Temperature-controlled shipping and storage across the whole fulfilment chain.

▪Research-grade purity: Fit for educational and research use that demands high-quality peptides.

Note: Product availability and specifications subject to change. Verify current product details on supplier website.

References

View Source ↗

PEG-MGF — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units.

There is no single correct amount — more water simply spreads the same 2 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units.

On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand.

Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product.

Divide the vial strength of 2 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose.

No. PEG-MGF is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

New protocols & dosing updates

Reconstitution charts, new peptide protocols and safety updates — straight to your inbox. No spam, unsubscribe anytime.

Written by Dr. Aimen Arij, PharmD

Related Growth Hormone protocols

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01Frequently Asked Questions About PEG-MGF

Straight answers on reconstitution, dosing, and safety, everything you need to research with confidence. For research reference only.

Source: peptidemind.com ↗
02Cortexin — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 10 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 10 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. Cortexin is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
03Ecnoglutide — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 10 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 10 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. Ecnoglutide is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
04GHK (Copper-Free) — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 50 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 50 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. GHK (Copper-Free) is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
05P21 — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 10 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 10 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. P21 is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
Research context

Read sources and limitations before applying a claim.

Where to Buy PEG MGF for Research

Research Use Only — not intended for human consumption Research peptides are sold for laboratory use only and are not intended for human consumption.

Source: mypeptidematch.com ↗

What the Evidence Actually Shows, and at What Level of Confidence

Separating mechanism from proof is the single most important discipline in reading this literature. The mechanistic case is strong and internally consistent. The clinical case is early, small, and deliberately modest in what it claims. Here it is worth being explicit about the hierarchy of evidence, from weakest to strongest: cell-culture experiments, animal models, uncontrolled human observations, small randomized safety trials, and finally large randomized efficacy trials with disease-relevant endpoints. NAD+ in Parkinson’s disease currently has a great deal at the lower rungs and very little at the top.1 At the preclinical level, NAD+ precursors have shown protective effects across multiple Parkinson’s models. Boosting NAD+ has improved mitochondrial function, reduced alpha-synuclein toxicity, and extended survival in fruit-fly and rodent systems, and the 2025 UPRmt/mitophagy work provided a specific mechanistic account of one way this protection might occur.1,5,6 These are meaningful signals, but animal models of Parkinson’s disease are notoriously imperfect predictors of human benefit; the graveyard of neuroprotective agents that worked in mice and failed in people is large. Preclinical success is a reason to run a human trial, not a substitute for one. The most important human data come from a small set of Norwegian trials. The NADPARK study, published in Cell Metabolism in 2022, was a randomized, double-blind, placebo-controlled phase I trial in 30 newly diagnosed, treatment-naive patients who received 1,000 mg of oral nicotinamide riboside or placebo for 30 days.1 Its purpose was to establish safety and target engagement. It succeeded on both counts: NR was well tolerated and produced a significant, though variable, increase in cerebral NAD+ measured by phosphorus magnetic resonance spectroscopy, alongside changes in related metabolites in cerebrospinal fluid. In the subgroup whose brain NAD+ actually rose (the responders), the investigators observed altered cerebral metabolism on FDG-PET and reported an associated mild clinical improvement, and blood and muscle transcriptomics showed upregulation of mitochondrial, lysosomal, and proteasomal gene programs.1 These are encouraging exploratory findings. They are not proof of efficacy: the trial was not powered or designed to demonstrate a change in disease progression, the clinical signal was in a post-hoc responder subgroup, and 30 days is a fraction of the timescale over which Parkinson’s disease evolves. The follow-up NR-SAFE trial, published in Nature Communications in 2023, tested a much higher dose, 3,000 mg of NR daily (1,500 mg twice daily), against placebo for four weeks in 20 patients, again primarily to assess safety.2 All 20 participants completed the study. There were 42 adverse events in total, 25 in the NR group and 17 in the placebo group, and critically all were graded mild, with no moderate or severe events and no statistically significant difference in adverse-event frequency between arms. No painful flushing was reported. The NR group showed a statistically significant improvement in total MDS-UPDRS score (from 51.0 to 40.3, p = 0.007) while placebo did not, but the authors themselves flagged this as preliminary and potentially confounded, including by differences in the timing of levodopa dosing relative to assessment.2 A responsible reading treats NR-SAFE as reassuring on high-dose safety and hypothesis-generating on efficacy, nothing more. The decisive test is the NOPARK study (NCT03568968), a phase III randomized, double-blind, placebo-controlled trial of 1,000 mg oral NR daily over 52 weeks in roughly 400 patients with early Parkinson’s disease across multiple Norwegian centers, with the change in total MDS-UPDRS as its primary endpoint.3 This is the appropriately sized, appropriately long, efficacy-focused trial the field needs. As of this writing the trial has completed enrollment and follow-up, but its primary clinical results have not been published, so no conclusion about efficacy can be drawn. Until those results appear, the honest evidence level for “NAD+ precursors slow Parkinson’s progression” is: plausible mechanism, safe in the short term at the doses tested, and unproven in humans. Alongside these interventional data sit epidemiological signals that are hypothesis-supporting but causally weak, discussed in the next section.

Source: dosagepeptide.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

How-to reference

How to convert mcg to mg (and back)

Because the factor is exactly 1000, every conversion is a decimal-point move of three places — no calculator strictly required once you see the pattern: mcg → mg: divide by 1000, i.e. move the decimal point three places to the left. 500 mcg → 0.5 mg; 100 mcg → 0.1 mg; 1500 mcg → 1.5 mg. mg → mcg: multiply by 1000, i.e. move the decimal point three places to the right. 0.5 mg → 500 mcg; 2 mg → 2000 mcg; 1.25 mg → 1250 mcg. The tool above does the same move for you and trims trailing zeros, so you can paste in any value — whole or fractional — and read the exact counterpart.

Source: dosagepeptide.com ↗
Dosage reference

PEG MGF Dosage Chart

PEG MGF is dosed at 200 mcg–500 mcg daily via subcutaneous injection in educational protocols. A 2 mg vial reconstituted with bacteriostatic water yields about 0.667 mg/mL. This information is for research and educational use only. Reconstitute: Add 3.0 mL bacteriostatic water (max vial capacity) → ~0.667 mg/mL concentration. Typical daily range: 200–500 mcg once daily (gradual titration over 8 weeks). Easy measuring: At 0.667 mg/mL, 1 unit = 0.01 mL ≈ 6.67 mcg on a U-100 insulin syringe. Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles. PEG MGF is a pegylated variant of mechano-growth factor, a muscle-derived IGF-1 splice isoform that is upregulated after mechanical stress or injury[2]. The unique C-terminal E peptide of MGF activates muscle satellite cells and local protein synthesis, initiating tissue repair and growth in addition to IGF-1 receptor signaling[3]. This educational protocol presents a once-daily subcutaneous approach using a practical dilution for clear insulin-syringe measurements. Research context: For evidence on mechanisms, human and preclinical research, limitations, and safety, read PEG-MGF Peptide: Benefits, Uses, Side Effects, Dosage, and Research.

Source: peptidedosages.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →